{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:00Z","timestamp":1785843900002,"version":"3.56.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Adalimumab (ADA) is an antitumor necrosis factor agent that is used for the treatment of inflammatory bowel disease. However, its cost has resulted in varying degrees of restricted access across global healthcare economies. Biosimilars are agents that contain a similar version of the active substance of an already approved original biologic agent and are intended to be used for the same indication as the reference product. In general, biosimilars follow the originator; therefore, information on its efficacy and safety had been few. Some studies have reported on replacement of the originator with a biosimilar of the same efficacy because of medical reasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 15-year-old girl with steroid-dependent ulcerative colitis that relapsed after vedolizumab was treated with ADA reference. Six weeks after starting ADA reference, her gastrointestinal symptoms had completely resolved, however, immediately after the eighth dose of ADA reference, redness, swelling, and pruritus were noted at the injection site on the left thigh.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Allergic reaction caused by the ADA reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>ADA reference was changed to ADA biosimilar LBAL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>ADA biosimilar LBAL was continued without any symptoms, such as local swelling, redness, or itching. In addition, there was no deterioration of gastrointestinal symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>We showed the efficacy and safety of ADA biosimilar LBAL as an alternative to ADA reference, which caused injection site reactions. Changing from ADA reference to ADA biosimilar because of adverse events may be an option that needs careful observation, considering that the originator and the biosimilar are not exactly the same.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000040400","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:02:29Z","timestamp":1730736149000},"page":"e40400","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Improved injection site reactions after switching from adalimumab reference to adalimumab biosimilar LBAL for ulcerative colitis: A case report"],"prefix":"10.1097","volume":"103","author":[{"given":"Yudai","family":"Hirakawa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-5522","authenticated-orcid":false,"given":"Toshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshiura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Kikkawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Saga University Hospital, Saga, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260804","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, Part 1: ambulatory care-an evidence-based guideline from European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R2-20260804","doi-asserted-by":"crossref","first-page":"105120","DOI":"10.1016\/j.phrs.2020.105120","article-title":"Biological therapy in pediatric age.","volume":"161","author":"Penagini","year":"2020","journal-title":"Pharmacol Res"},{"key":"R3-20260804","first-page":"3300","article-title":"Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in the period 2016-2019.","volume":"25","author":"Pilunni","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R4-20260804","doi-asserted-by":"crossref","first-page":"e050949","DOI":"10.1136\/bmjopen-2021-050949","article-title":"Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients\u2019 satisfaction: a cross-sectional survey by patient organisations.","volume":"12","author":"Kaneko","year":"2022","journal-title":"BMJ Open"},{"key":"R5-20260804","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/ecco-jcc\/jjaa001","article-title":"Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre.","volume":"14","author":"Lukas","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R6-20260804","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update.","volume":"11","author":"Danese","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R7-20260804","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2017.02.003","article-title":"Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-\u03b1 agents in rheumatic diseases; a systematic review and meta-analysis.","volume":"79","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"key":"R8-20260804","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.clinthera.2022.06.004","article-title":"Vedolizumab as the first-line of biologicals for pediatric patients with ulcerative colitis.","volume":"44","author":"Kakiuchi","year":"2022","journal-title":"Clin Ther"},{"issue":"suppl_4","key":"R9-20260804","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20260804","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: key regulatory considerations and similarity assessment tools.","volume":"114","author":"Kirchhoff","year":"2017","journal-title":"Biotechnol Bioeng"},{"key":"R11-20260804","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19768354.2021.1943709","article-title":"Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira\u00ae).","volume":"25","author":"Kwon","year":"2021","journal-title":"Anim Cells Syst (Seoul)"},{"key":"R12-20260804","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"R13-20260804","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archderm.144.9.1190","article-title":"Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab.","volume":"144","author":"Paltiel","year":"2008","journal-title":"Arch Dermatol"},{"key":"R14-20260804","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2007.01536.x","article-title":"Injection site reactions to TNF-alpha blocking agents with positive skin tests.","volume":"63","author":"Benucci","year":"2008","journal-title":"Allergy"},{"key":"R15-20260804","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies.","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"R16-20260804","doi-asserted-by":"crossref","first-page":"670703","DOI":"10.3389\/fped.2021.670703","article-title":"Case report: infusion-related reactions to intravenous infliximab and subcutaneous ustekinumab in pediatric Crohn\u2019s disease.","volume":"9","author":"Kakiuchi","year":"2021","journal-title":"Front Pediatr"},{"key":"R17-20260804","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"R18-20260804","doi-asserted-by":"crossref","first-page":"102404","DOI":"10.1016\/j.autrev.2019.102404","article-title":"Biosimilars vs originators: are they the same?","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R19-20260804","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12876-016-0455-y","article-title":"Clinical course and outcomes of diagnosing inflammatory bowel disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.","volume":"16","author":"Gasparetto","year":"2016","journal-title":"BMC Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000040400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:00:52Z","timestamp":1785841252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000040400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":19,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040400","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}